Doing deals is one of the cornerstones of biotechnology, and can cover a myriad of activities from obtaining private or public equity, to collaborations and joint ventures, and in- and out-licensing of technology and products. But while transactions can increase the value of a company, too often the deal itself can lead to a decline in shareholder value. [ + ]

Monash University scientists, investigating how the size of blood clots is regulated, have identified a new target for anti-clotting drugs that could help in the treatment of patients at risk of heart attack or stroke.

In what it hopes is the first step towards a Nasdaq listing, Melbourne platform technology biotech Eiffel Technologies has appointed New York-based introduction agents Global Markets Capital Corporation (GMCC) to represent it on the US investor market. [ + ]

Melbourne biotechnology company Genetic Technologies (ASX: GTG) has appointed two Australian scientists to assist it with the set up of its new cancer susceptibility genetic testing service. [ + ]

Innovative RF radiation techniques have resulted in positive weight reduction results, according to a recent University of Adelaide study. [ + ]

A group of Australia's top researchers have embarked on an ambitious project to make light do things that were previously impossible.

Platform technology company Proteome Systems is to offer its first contract-fee based operation in a joint initiative with Massachusetts-based Charles River Laboratories (CRL). [ + ]

Possible links between the pathology of the eye and the brain have been identified by Prana consultants working on Alzheimer's patients. [ + ]

Scientists at the Monash Institute of Reproduction and Development's Centre for Functional Genomics and Human Disease have identified a transcription factor gene on chromosome 21 that may help to explain the immune system defects common to Down syndrome patients. [ + ]

Listed biotech Optiscan Imaging, one of many struggling to conserve cash while waiting for their IP to reach commercial fruition, appears to have won some breathing space with a tough new strategy. [ + ]

Monash University scientists have identified potential new targets for the development of drugs to reduce blood clotting in patients at risk of heart attack or stroke. [ + ]

Industry protests are coming loud and long following reports that the federal government's PIIP (Pharmaceutical Investment Incentive Scheme) may be axed in the next budget. [ + ]

A trans-Tasman collaboration between New Zealand's Genesis R&D and Sydney-based EvoGenix will target a novel target for anti-inflammatory therapeutics. [ + ]

New Zealand's largest biotechnology company, Genesis Research and Development, is spinning out its plant division into a separate, fully owned company to maximise the value of its assets, according to CEO Dr Jim Watson. [ + ]

Australian-based research instrument specialist Corbett Research has sealed a hardware deal with prime Swedish genetic analysis company Pyrosequencing. [ + ]